In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtechs Must Partner With US Providers As Outcomes Revolution Ramps Up

Executive Summary

US hospitals have suddenly started to care economically about the episodes of care that patients receive – an adjustment that requires medtech companies to adapt accordingly. So says ZS Associates in a new report about how companies need to work in step with providers as the transition to outcomes-based care accelerates.

You may also be interested in...



US Medtech Under Trump: Below The Radar Or In The Line Of Fire?

The return of a Republican president to power in last month's US elections showed – for the second time in 2016 – that punditry can be misleading and opinion polls do not always equate with reality. With just a few weeks to President Trump's inauguration, ZS Associates' Brian Chapman gives an early appraisal of how the new administration might view the health care brief in general and the medtech industry in particular.

CMS Incubator Helps ‘equIP’ Health Care Innovators With AI Power

The trend among device innovators to focus on diagnostic technologies that improve imaging, offer better visualization of tissues and avoid the need for biopsies is well noted by full-service law firm CMS. Its equIP program supports many start-ups incorporating AI into products and development processes.

Launch Of Team-AB Offers United Voice For UK Approved Bodies

Forum officially unveiled on 19 February to represent growing band of organizations designated against the UKCA mark.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

IV004918

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel